Synartro Overview

  • Founded

  • 2011

Founded
  • Status

  • Private

  • Employees

  • 7

Employees
  • Latest Deal Type

  • Later Stage VC

  • Investors

  • 3

Synartro General Information

Description

Developer of drugs and a drug delivery platform designed to treat osteoarthritis in humans and animals. The company develops local injection treatments that provide superior and sustained efficacy without systemic side effects which leads to improved treatments using patented delivery technology that offers a sustained drug release combined with existing proven drugs, enabling clinicians to slow down or stop the disease progression entirely.

Contact Information

Website
www.synartro.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • Svetsarvagen 15, 2 tr
  • 171 41 Solna
  • Sweden
+46 076-027 00 00

Synartro Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synartro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-May-2023 000.00 Completed Pre-Clinical Trials
4. Seed Round 25-Oct-2021 00.000 000.00 00.00 Completed Pre-Clinical Trials
3. Seed Round 04-Nov-2020 00.000 00.000 00.000 Completed Pre-Clinical Trials
2. Seed Round 05-May-2020 $6M $6M 0000 Completed Pre-Clinical Trials
1. Merger/Acquisition 18-Mar-2015 Completed Pre-Clinical Trials
To view Synartro’s complete valuation and funding history, request access »

Synartro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs and a drug delivery platform designed to treat osteoarthritis in humans and animals. The company deve
Drug Discovery
Solna, Sweden
7 As of 2023
000.00
0000000000 0 000.00

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut eni
0000000000000
Basel, Switzerland
000000&0

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000000000 000000000
Tokyo, Japan
0000 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synartro Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mestex Pharmaceutical Corporate Backed or Acquired Basel, Switzerland 000000&0
000000000 Corporation Tokyo, Japan 0000 00000000
You’re viewing 2 of 2 competitors. Get the full list »

Synartro Patents

  • 14

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Synartro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202216467-D0 Pharmaceutical formulation Pending 04-Nov-2022
GB-202211970-D0 Sterilisation method Pending 16-Aug-2022
ES-2905606-T3 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions Active 27-Feb-2014 0000000000
US-11229656-B2 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions Active 27-Feb-2014 0000000000
US-10660906-B2 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions Active 27-Feb-2014 A61K31/573
To view Synartro’s complete patent history, request access »

Synartro Executive Team (7)

Name Title Board Seat Contact Info
Mia Brundin Chief Executive Officer and External Managing Director
Fredrik Lehmann Ph.D Co-Founder, Chairman and President
Magnus Hurst Chief Financial Officer
Bengt Lindqvist Ph.D Chief Scientific Officer & Board Member
You’re viewing 4 of 7 executive team members. Get the full list »

Synartro Board Members (6)

Name Representing Role Since
Bengt Lindqvist Ph.D Synartro Chief Scientific Officer & Board Member 000 0000
Fredrik Lehmann Ph.D Synartro Co-Founder, Chairman and President 000 0000
Lars Jansson Self Board Member 000 0000
Mats Persson Self Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Synartro Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synartro Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Phase2Phase Biopharma Venture Capital Minority 000 0000 000000 0
Sciety Venture Capital Minority 000 0000 000000 0
Linc (Sweden) Venture Capital Minority 000 0000 000000 0
To view Synartro’s complete investors history, request access »

Ready to get started?

Request a free trial